The U.S. Food and Drug Administration (FDA) has issued two guidance to accelerate the COVID-19 treatment process as well as develop the drugs to prevent the spread. 
    
“Accelerating the investigation of safe and effective therapies that could benefit people affected by the COVID-19 pandemic is one of the FDA’s highest priorities. We are committed to maximizing our regulatory flexibility and using every tool at our disposal to speed the development and availability of these medical products and believe these new guidances will help innovators and researchers do just that,” said FDA Commissioner Stephen Hahn.